Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Vaccines and Molecular Therapeutics
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1448408
This article is part of the Research Topic SARS-CoV-2 Vaccines Beyond the Pandemic Era View all 8 articles

Comparison of Antibody Responses of Heterologous and Homologous Covid-19 Booster Vaccination: An Observational Study

Provisionally accepted
Nayab B. Rizvi Nayab B. Rizvi 1,2*Maryam Bibi Maryam Bibi 1,2Muhmmad Z. Rana Muhmmad Z. Rana 3Sehrish Zaffar Sehrish Zaffar 3Hassam Farooq Hassam Farooq 1,2
  • 1 University of the Punjab, Lahore, Pakistan
  • 2 School of Chemistry, University of the Punjab, Lahore, Lahore, Punjab, Pakistan
  • 3 Combined Military Hospital (Lahore), Lahore, Pakistan

The final, formatted version of the article will be published soon.

    Objective: Pakistan has been seriously affected by the COVID-19 pandemic, with numerous waves of infection. Using different vaccine and booster doses was a key component to control and combat this pandemic. This study aims to monitor the heterologous and homologous booster vaccination doses that generate immune responses in healthy adults after 9 months of vaccination.In this cross-sectional, observational study a total of 173 samples were collected.Participants from both genders (Male and Female) between the ages of 18 to 25 years were enrolled for the study. Participants who had booster shots of homologous Sinopharm BBIBP CorV and heterologous Pfizer-BioNTech vaccines were included only, with the use of a Roche Cobas-e601 analyzer, the antibody titers in the blood serum were quantified by the ECLIA method. IBM SPSS 22 was utilized for descriptive statistical analysis and P< 0.05 was considered significant.In this study the IgG antibody levels were measured against the full length of receptor binding domain (RBD) of the spike (S) protein. The mean antibody titer in the Pfizer group was 9764±10976 U/mL and 5762±4302 U/mL in the Sinopharm group. The Mean IgG antibody levels of the Pfizer-vaccinated group were significantly higher than the Sinopharm-vaccinated group (P=0.000, each). Comparing the Sinopharm BBIBP CorV booster dosage to the Pfizer booster, Pfizer BNT162b2demonstrated a stronger immune response. However, there were no immunological gender-specific significant differences. The administration of a third dosage of Pfizer BNT162b2 after two doses of BBIBP CorVThe administration of a third dosage of Pfizer BNT162b2 after two doses of BBIBP-CorV is recommended to boost the humoral immune response in the general population while there was no gender-specific difference observed. More effectiveness can be attained by administering additional doses due to the antibody decay.

    Keywords: COVID - 19, virus, Vaccine, Booster, Homologus Model

    Received: 13 Jun 2024; Accepted: 04 Oct 2024.

    Copyright: © 2024 Rizvi, Bibi, Rana, Zaffar and Farooq. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Nayab B. Rizvi, University of the Punjab, Lahore, Pakistan

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.